Evidence map›Paper›PMID 33148511›Full record

ArticleClinical immunology (Orlando, Fla.)2020

Ex vivo assays to detect complement activation in complementopathies.

Xuan Yuan, Jia Yu, Gloria Gerber, Shruti Chaturvedi, Michael Cole, Hang Chen, Ara Metjian, C John Sperati, Evan M Braunstein, Robert A Brodsky

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xuan YuanDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Jia YuDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Gloria GerberDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Shruti ChaturvediDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Michael ColeDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Hang ChenDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ara MetjianDivision of Hematology, Department of Medicine, Duke University, Durham, NC, USA.
C John SperatiDivision of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Evan M BraunsteinDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: brodsro@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USDuke University · US

Funding

Complementopathies: Genotype and PhenotypeR01HL133113 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BRODSKY, ROBERT A · 2016 to 2020
$2.0M
Investigation of ERBB2 and ERBB3 in hematopoiesis and predisposition to hematologic diseaseK08HL138142 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BRAUNSTEIN, EVAN M · 2018 to 2021
$690k
NHLBI NIH HHS K08 HL138142NHLBI NIH HHS R01 HL133113
6 · The paper itself

Abstract

In complement-driven thrombotic microangiopathies, failure to regulate complement activation leads to end-organ damage. The modified Ham (mHam) test measures complement-mediated killing of a nucleated cell in vitro but lacks a confirmatory assay and reliable positive controls. We demonstrate that C5b-9 accumulation on the surface of TF1 PIGAnull cells correlates with cell killing in the mHam. We also show that Sialidase treatment of cells or addition of Shiga toxin 1 to human serum serve as a more reliable positive control for the mHam than cobra venom factor or lipopolysaccharide. Simultaneously performing the mHam and measuring C5b-9 accumulation either in GVB

Indexed as

AdultAntiphospholipid SyndromeAtypical Hemolytic Uremic SyndromeBiological AssayCell Line, TumorComplement ActivationComplement C3cComplement C4bComplement Inactivating AgentsComplement Membrane Attack ComplexElapid VenomsFemaleHumansLipopolysaccharidesMaleMiddle Agedcobra venom factorComplement C3cComplement C4bcomplement C4dComplement Inactivating AgentsComplement Membrane Attack ComplexElapid VenomsLipopolysaccharidesNeuraminidasePeptide FragmentsShiga Toxin 1Atypical hemolytic uremic syndromeComplementComplement inhibitorsModified HAM assayShiga toxin 1Sialidase

Identifiers

PMID33148511
PMCPMC8609776
OpenAlexW3094633332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.